Back
ESC Premium Access

Q&A - Challenging the current treatment paradigm - SGLT2 inhibition in heart failure.

logo

Session: Challenging the current treatment paradigm - SGLT2 inhibition in heart failure (EBAC Accredited)
Topic: Miscellaneous
Speaker: Professor M. Metra (Brescia, IT) Professor K. Ray (London, GB)
Sponsored by AstraZeneca
Event: ESC Congress 2017

Congress Presentation

0

About the speakers

Professor Marco Metra

University of Brescia, Brescia (Italy)
109 presentations
19 followers

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
59 presentations
5 followers

4 more presentations in this session

Chair’s introduction - Challenging the current treatment paradigm - SGLT2 inhibition in heart failure.

Speaker: Professor M. Metra (Brescia, IT)

Access
Slides
Video
0
Thumbnail

The ongoing problem of heart failure.

Speaker: Professor K. Ray (London, GB)

Access
Slides
Video
0
Thumbnail

SGLT2 inhibition: the potential to change the heart failure landscape?

Speaker: Professor J. McMurray (Glasgow, GB)

Access
Slides
Video
0
Thumbnail

Summary & close - Challenging the current treatment paradigm - SGLT2 inhibition in heart failure.

Speaker: Professor M. Metra (Brescia, IT)

Access
Slides
Video
0
Thumbnail

Access the full session

Challenging the current treatment paradigm - SGLT2 inhibition in heart failure (EBAC Accredited)

Speakers: Professor M. Metra, Professor K. Ray, Professor M. Metra, Professor K. Ray, Professor J. McMurray...
Access
0
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk